Regulating advertisements: The case of smoking cessation products

Journal of Regulatory Economics

Volumn 31, Issue 2, 2007, Pages 185-208

  Avery, Rosemary ^a   Kenkel, Donald ^a   Lillard, Dean ^a   Mathios, Alan ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Advertising; FDA; Regulation; Smoking Cessation

Indexed keywords

EID: 33947146724     PISSN: 0922680X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11149-006-9021-9     Document Type: Article

References (51)

1. Avery, R. J., Kenkel. D. S., Lillard, D., & Mathios, A. (2006). Private profits and public health: Does advertising smoking cessation products encourage smokers to quit? NBER Working Paper 11938.
2. Becker, G. S., & Murphy, K. M. (1988). A theory of rational addiction. Journal of Political Economy, 96(4), 675-700.
3. Berndt, E. R., Bui, L., Reiley, D. R., & Urban, G. L. (1995). Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review Papers and Proceedings, 85(2), 100-105.
4. Bhattacharya, J., & Vogt, W. B. (2003). A simple model of pharmaceutical price dynamics. Journal of Law and Economics, 46(2), 599-626.
5. Calfee, J. E., Winston, C., & Stempski, R. (2002). Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. Journal of Law and Economics, 45(2, Part 2), 673-690.
6. Chaloupka, F. J., & Warner, K. (2000). The economics of smoking. In A. J. Culyer, & J. Newhouse (Eds.), Handbook of health economics. Elsevier.
7. Chintagunta, P. K., & Vilcassim, N. J. (1994). Marketing investment decisions in a dynamic duopoly: A model and empirical analysis. International Journal of Research in Marketing, 11(3), 287-306.
8. Danzon, P. M., & Pauly, M. V. (2002). Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics, 45(2, Part 2), 587-614.
9. Federal Register (2002). 67(95), 34942-34944.
10. Gallet, C. A., & List J. A. (2003). Cigarette demand: A meta-analysis of elasticities. Health Economics, 12(10), 821-835.
11. Grabowski, H. G., & Vernon, J. M. (1983). The regulation of pharmaceutical; Balancing the benefits and risks. Washington D.C.: American Enterprise Institute for Public Policy Research.
12. Grossman, D., Ellertson, C., Abuabara, K., Blanchard, K., & Rivas, F. T. (2006). Barriers to contraceptive use in product labeling and practice guidelines. American Journal of Public Health, 96(5), 791-799.
13. HarpWeek. (2004). Web page accessed July 27, 2005. http://tobacco. harpweek.com/HubPages/CommentaryPage.asp?Commentary=Addiction.
14. Hu, T., Sung, H., Keeler, T. E., & Marciniak M. (2000). Cigarette consumption and sales of nicotine replacement products. Tobacco Control, 9(Supplement II), ii60-ii63.
15. Ippolito, P. M., & Mathios A. (1990). Information, advertising and health choices: A study of the cereal market. RAND Journal of Economics, 27(3), 459-480.
16. Ippolito, P. M., & Mathios, A. (1991). Health claims in food marketing: Evidence on knowledge and behavior in the cereal market. Journal of Public Policy and Marketing, 10(1), 15-32.
17. Ippolito, P. M., & Mathios, A. (1995). Information and advertising: "Die case of fat consumption in the United States. American Economic Review: Papers and Proceedings, 85(2), 91-95.
18. Iizuka, T., & Jin, G. Z. (2005). Drug advertising and health habits. NBER Working Paper 11770.
19. Jones, A. (2000). Health econometrics. In A. J. Culyer & J. Newhouse (Eds.), Handbook of health economics. Elsevier.
20. Keeler, T. E., Hu, T., Keith, A., Manning, R., Marciniak, M., Ong, M., & Sung, H. (2002). The benefits of switching smoking cessation drugs to over-the-counter status. Health Economics, 11(5), 389-402.
21. Keith, A. (1995). Regulating information about aspirin and the prevention of heart attack. American Economic Review Papers and Proceedings, 85(2), 96-99.
22. Lee, C. (2002). Advertising, its determinants, and market structure. Review of Industrial Organization, 21(1), 89-101.
23. Ling, D. C., Berndt, E. R., & Kyle, M. K. (2002). Deregulating direct-to-consumer marketing of prescription drugs: Effects on prescription and over-the-counter product sales. Journal of Law and Economics, 45(2), 691-723.
24. Mathios, A. (1998). The importance of nutrition labeling and health claim regulations on product choice: An analysis of the cooking oil market. Agricultural and Resource Economics Review, 27(2), 159-168.
25. Mathios, A. (2000). The impact of mandatory disclosure laws on product choices: An analysis of the salad dressing market. Journal of Law and Economics, 43(2), 651-678.
26. McPhillips-Tangrum, C. (1998). Results from the first annual survey on addressing tobacco in managed care. Tobacco Control, 7 (Supplement 1), S11-S13.
27. Mullahy, J. (1997). Heterogeneity, excess zeros, and the structure of count data models. Journal of Applied Econometrics, 12(3), 337-350.
28. National Center for Health Statistics. (2001). Healthy people 2000 final review. Hyattsville, Maryland: Public Health Service.
29. Nelson, J. P. (2003). Cigarette demand, structural change, and advertising bans: International evidence, 1970-1995. Contributions to Economic Analysis & Policy, 2(1), Article 10.
30. Peltzman, S. (1973). An evaluation of consumer protection legislation: The 1962 drug amendments. Journal of Political Economy, 81(5), 1049-1091.
31. Roberts, M. J., & Samuelson, L. (1988). An empirical analysis of dynamic, nonprice competition in an oligopolistic industry. RAND Journal of Economics, 19(2), 200-220.
32. Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M., & Frank, R. G. (2003). Demand effects of recent changes in prescription drug promotion. In A. M. Garber & D. M. Cutler (Eds.), Frontiers in health policy research (Vol. 6). Cambridge, Massachusetts: MIT Press.
33. Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Rank, R. G., & Epstein, A. M. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346(7), 498-505.
34. Rubin, P. (1991). The FDA's prescription for consumer ignorance. Consumers Research Magazine 75(6), 17-20.
35. Rubin, P. (1995). PDA advertising restrictions: Ignorance is death. In R. Higgs (Ed.), Hazardous to our health? FDA regulation of health care products. Oakland, California: The Independent Institute.
36. Saffer, H., & Chaloupka, F. (2000). The effects of tobacco advertising bans on tobacco consumption. Journal of Health Economics, 19(6), 1117-1137.
37. Schmalensee, R. (1983). Advertising and entry deterrence: An exploratory model. Journal of Political Economy, 91(4), 636-653.
38. Schoenborn, C. A., Vickerie, J. L., & Barnes, P. M. (2003). Cigarette smoking behavior of adults: United States 1997-98. Advance. Data from Vital and Health Statistics, Number 331, February 7.
39. Schwartz, J. L. (1969). A critical review and evaluation of smoking control methods. Public. Health Reports, 84(6), 483-506.
40. Schwartz, J. L. (1987). Review and evaluation of smoking cessation methods: The United States and Canada, 1978-1985. Published by Division of Cancer Prevention and Control, National Cancer Institute, U.S. Department of Health and Human Services. NIH Publication No. 87-2940.
41. Schwartz, J. L., & Rider, G. (1978). Review and evaluation of smoking control methods: The United. States and Canada, 1969-1977. Bureau of Health, Education, Center for Disease Control, Public Health Service, USDHHS Publ. No. (CDC) 79-8369.
42. Scott-Morton, F. M. (2000). Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization, 18(1), 1085-1104.
43. Tabarrok, A. (2000). Assessing the FDA via the anomaly of off-label drug prescribing. The Independent Review, 5(1), 25-53.
44. Tauras, J. A., & Chaloupka, F. (2003). The demand for nicotine replacement therapies. Nicotine and Tobacco Research, 5(2), 237-243.
45. U.S. Department of Health and Human Services [USDHHS]. (1989). Reducing the health consequences of smoking. 25 years of progress. A report of the surgeon general. 1989. U.S. Department of Health and Human Service, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
46. U.S. Department of Health and Human Services [USDHHS]. (2000a). Clinical practice guideline: Treating tobacco use. and. dependence. Washington, DC: U.S. Government Printing Office.
47. U.S. Department of Health and Human Services [USDHHS]. (2000b). Healthy people 2010 (2nd ed.). With understanding and improving health and objectives for improving health. 2 vols. Washington, DC: U.S. Government Printing Office.
48. U.S. Department of Health and Human Services [USDHHS]. (2000c). Reducing tobacco use: A report of the surgeon general. Atlanta, Georgia: U.S. Department of Health and Human Service, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
49. Wooldridge, J. (2002). Econometric analysis of cross section and panel data. Cambridge, Massachusetts: The MIT Press.
50. Wosinska, M. (2003). Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. Harvard Business School Working Paper No., 02-04.
51. Wosinska, M. (2005). Direct-to-consumer advertising and drug therapy compliance. Journal of Marketing Research, 42(3), 323-332.